LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXT · Pharmaceutical Preparations · 12.4M shares · +19%/yr ↑ shares · EDGAR filings ↗
Net buyback after stock comp: -$394K (gross $25K, SBC $418K)
Grade
D40Clinical/early-stage biotech — micro clinical-stage, deep losses.
Strengths
- Liquidity — current ratio 3.9 (50th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- No interest coverageInterest coverage -557.72 (cannot cover interest)
- Going concernThere is substantial doubt about our ability to continue as a going concern
- Exec changeRecent 8-K item 5.02 8-K ↗
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Notable holderHeld by 3 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, STATE STREET CORP (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-62.9%
Return on assets
-47.7%
Interest coverage
-557.7×
Current ratio
3.9×
Tangible book value
$10M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-29 | Porter Stuart D | Grant | 25K | — |
| 2026-04-15 | Stazzone Peter | Grant | 50K | — |
| 2026-04-15 | Sawyer Jason David | Grant | 25K | — |
| 2026-04-15 | Pursglove Geordan Garrett | Grant | 350K | — |
| 2026-04-15 | Primus Guy Warren | Grant | 25K | — |
| 2026-04-15 | Holloway Michael Andrew | Grant | 25K | — |
| 2026-04-15 | Felix Lourdes | Grant | 25K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT03886662 ↗ | A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Myelodysplastic Syndromes | PHASE1/PHASE2 | Recruiting | 2021-05-01 |
| NCT01837667 ↗ | Phase I Study of LB-100 With Docetaxel in Solid Tumors Tumors, Neoplasms | PHASE1 | Completed | 2016-09-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-18 | Material agreementReg FDExhibits | filing ↗ |
| 2026-06-16 | Material agreement3.02Reg FDExhibits | filing ↗ |
| 2026-06-04 | Material agreementOtherExhibits | filing ↗ |
| 2026-06-01 | Exec/director changeReg FDExhibits | filing ↗ |
| 2026-04-17 | Exec/director changeExhibits | filing ↗ |
| 2026-03-20 | Exec/director changeExhibits | filing ↗ |
| 2026-03-10 | Material agreementExhibits | filing ↗ |
| 2026-02-18 | Material agreementReg FDExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-18 | 2026-06-17 | 0001493152-26-029308 ↗ |
| 8-K | 2026-06-16 | 2026-06-11 | 0001493152-26-028878 ↗ |
| 8-K | 2026-06-04 | 2026-06-02 | 0001493152-26-027307 ↗ |
| 8-K | 2026-06-01 | 2026-05-29 | 0001493152-26-026544 ↗ |
| 10-Q | 2026-05-14 | 2026-03-31 | 0001493152-26-023150 ↗ |
| 8-K | 2026-04-17 | 2026-04-15 | 0001493152-26-017833 ↗ |
| 10-K | 2026-03-31 | 2025-12-31 | 0001493152-26-014052 ↗ |
| 8-K | 2026-03-20 | 2026-03-18 | 0001493152-26-011829 ↗ |
| 8-K | 2026-03-10 | 2026-03-06 | 0001493152-26-009526 ↗ |
| 8-K | 2026-02-18 | 2026-02-12 | 0001493152-26-007268 ↗ |
| 8-K | 2025-12-31 | 2025-12-30 | 0001493152-25-029778 ↗ |
| 8-K | 2025-12-23 | 2025-12-17 | 0001493152-25-028999 ↗ |